Affiliation:
1. Guang’anmen Hospital
2. China Academy of Chinese Medical Sciences
Abstract
Abstract
The observational association between circulating metabolites and non-alcoholic fatty liver disease (NAFLD) has been somewhat demonstrated. However, it is unclear whether there is a causal relationship for this association. In this study, we used a two-sample bidirectional MR analysis approach to assess the association between 1,400 blood metabolites and NAFLD. Causality was estimated using the inverse variance weighted (IVW) method, and sensitivity analyses were applied after performing false discovery rate (FDR) correction to assess heterogeneity and pleiotropy. In addition, we performed linkage disequilibrium regression (LDSC) analysis, confounder analysis and metabolic pathway analysis. Corrected for FDR, we identified seven metabolites suggestively associated with NAFLD, including imidazole lactate levels (OR = 0.90,95% CI = 0.85–0.95,P = 0.0004), cysteine-glutathione disulfide levels (OR = 0.80, 95%CI = 0.72–0.89,P = 0.0001), 3-indoleglyoxylic acid levels(OR = 0.87,95%CI = 0.80–0.94,P = 0.0009), lithocholate sulfate (1) levels (OR = 1.18,95%CI = 1.07–1.30, P = 0.006), bilirubin degradation product, C17H18N2O4 (2) levels (OR = 1.14,95%CI = 1.07–1.21,P = 4.02E-05), bilirubin degradation product, C17H18N2O4 (3) levels (OR = 1.13, 95%CI = 1.06–1.21,P = 0.0001), and biliverdin levels (OR = 1.12, 95% CI = 1.05–1.18, P = 0.023). This study provides evidence support for the causal effect of seven metabolites on NAFLD, and provides new perspectives for combining genomics and metabolomics to explore the biological mechanisms of NAFLD.
Publisher
Research Square Platform LLC
Reference63 articles.
1. Non-alcoholic fatty liver disease: Definition and subtypes;Han SK;Clin Mol Hepatol,2023
2. Current treatment of non-alcoholic fatty liver disease;Paternostro R;J Intern Med,2022
3. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;EASL-EASD-EASO;Diabetologia,2016
4. Non-alcoholic fatty liver disease: the pathologist's perspective;Leow WQ;Clin Mol Hepatol,2023
5. A global view of the interplay between non-alcoholic fatty liver disease and diabetes;Stefan N;Lancet Diabetes Endocrinol,2022